Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Ethos Technologies Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Ethos Technologies Inc. (LIFE $10.89), a vertically integrated life insurance platform providing underwriting, distribution, and policy administration services to insurers and agents.

    Read more

  • Navigating China’s Restrictions and the U.S. Response

    The Department of Defense has invested more than $439 million in rare earth projects since 2020. Learn more about how these elements are essential to modern technology.

    Read more

  • William Blair Initiates Coverage of Two Companies in the Medical Technology Industry

    William Blair initiated research coverage of Stryker Corporation (SYK $377.32) and Zimmer Biomet Holdings, Inc. (ZBH $98.25), two leading global medical technology companies.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures